周二，H.C. Wainwright维持了对Plus Therapeutics Inc. (NASDAQ:PSTV)的买入评级和8.00美元的股票目标价。这是在该公司于11月21日至24日举行的神经肿瘤学会年会上发表演讲之后。演讲内容包括了ReSPECT-LM第一阶段研究的最新进展，该研究评估了rhenium obisbemeda (186RNL)在治疗脑膜转移瘤 (LM)方面的效果。

Receives FDA agreement to initiate the ReSPECT-LM Phase 1 multiple administration dose escalation trial of Rhenium (186Re) Obisbemeda for LM ...

Obtained agreement from FDA to initiate a Phase 1 trial evaluating multiple doses of Rhenium (186Re) Obisbemeda for the treatment of patients with leptomeningeal metastases (LM) Presented positive ReS ...

Obtained agreement from FDA to initiate a Phase 1 trial evaluating multiple doses of Rhenium (186Re) Obisbemeda for the treatment of patients ...

The Ministry of Mines and International Energy Agency IEA signed an MoU on Wednesday for cooperation in the area of critical ...

Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients: Receive the the ...